Drug Interaction Report
1 potential interaction and/or warning found for the following 2 drugs:
- Avtozma (tocilizumab)
- chloramphenicol
Interactions between your drugs
chloramphenicol tocilizumab
Applies to: chloramphenicol, Avtozma (tocilizumab)
GENERALLY AVOID: Coadministration of chloramphenicol with other agents that can cause bone marrow depression, aplastic anemia, or agranulocytosis may increase the risk and/or severity of hematologic toxicity. Serious and fatal blood dyscrasias (aplastic anemia, hypoplastic anemia, thrombocytopenia, granulocytopenia, and bone marrow depression) have been reported after short-term and long-term systemic therapy with chloramphenicol.
MANAGEMENT: Concurrent use of chloramphenicol with other agents that can cause bone marrow depression, aplastic anemia, or agranulocytosis, such as sulfonamides, nucleoside reverse transcriptase inhibitors, procainamide, phenylbutazone, clozapine, and depot formulations of antipsychotic drugs, should be avoided.
References (4)
- (2002) "Product Information. Chloromycetin (chloramphenicol)." Parke-Davis
- (2022) "Product Information. Chloromycetin (chloramphenicol)." Pfizer Canada Inc
- (2015) "Product Information. Chloromycetin Succinate (chloramphenicol)." Link Medical Products Pty Ltd T/A Link Pharmaceuticals
- (2023) "Product Information. Chloramphenicol (chloramphenicol)." Eramol (UK) Ltd
Drug and food interactions
No alcohol/food interactions were found with the drugs in your list. However, this does not necessarily mean no food interactions exist. Always consult your healthcare provider.
Therapeutic duplication warnings
No duplication warnings were found for your selected drugs.
Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.
Report options
- Switch to consumer interaction data
- Email this report to a friend, doctor, or patient
- Ask questions, find answers
Drug Interaction Classification
| Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
| Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
| Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
| No interaction information available. |
See also:
Humira
Humira is a tumor necrosis factor blocker used to treat many inflammatory conditions in adults ...
Rinvoq
Rinvoq (upadacitinib) is used to treat rheumatoid arthritis, psoriatic arthritis, atopic ...
Ozempic
Learn about Ozempic (semaglutide) for type 2 diabetes treatment, weight management, cardiovascular ...
Deltasone
Deltasone is used for acute lymphocytic leukemia, adrenocortical insufficiency, allergic reactions ...
Actemra
Actemra is used to treat COVID-19, rheumatoid arthritis, systemic juvenile idiopathic arthritis ...
Rayos
Rayos (prednisone, delayed-release) is used to treat rheumatoid arthritis, polymyalgia rheumatica ...
Tyenne
Tyenne is approved to treat adults with moderately to severely active rheumatoid arthritis, Giant ...
Sterapred
Sterapred is used for acute lymphocytic leukemia, adrenocortical insufficiency, allergic reactions ...
Tofidence
Tofidence (tocilizumab-bavi) is administered as an intravenous infusion by a healthcare provider ...
Upadacitinib
Upadacitinib is an oral Janus kinase (JAK) inhibitor that may be used alone or in combination with ...
Learn more
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Check Interactions
To view an interaction report containing 4 (or more) medications, please sign in or create an account.
Save Interactions List
Sign in to your account to save this drug interaction list.